Exchange: NASDAQ·Updated 06:58 PM EDT
News
all
press releases
Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimates
Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +14.52% and +2.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why
Pacific Biosciences of California (PACB) reached $1.39 at the closing of the latest trading day, reflecting a +2.21% change compared to its last close.
Zacks
Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.36, indicating a -5.56% shift from the previous trading day.
Zacks
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Pacific Biosciences of California (PACB) concluded the recent trading session at $1.49, signifying a -4.49% move from its prior day's close.
Zacks
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care
RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.
Zacks
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers
Natera's Signatera became the first personalized MRD test for solid tumors to earn EU IVDR certification, supporting broader expansion across Europe.
Zacks
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI's portfolio, acquisitions, R&D strategy and WRAPSODY upside support growth, though tariffs, China pressure and OEM headwinds persist.
Zacks
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth
West Pharmaceutical completes the SmartDose 3.5mL sale to AbbVie, sharpening its focus on higher-growth on-body drug delivery technologies.
Zacks
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.
Zacks
CareDx Completes Naveris Acquisition and Expands Oncology Reach
CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.
Zacks
<
1
2
>

Advertisement|Remove ads.